We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+2.01%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.42B
AUM Growth
+$183M
Cap. Flow
+$291M
Cap. Flow %
20.46%
Top 10 Hldgs %
37.91%
Holding
267
New
57
Increased
30
Reduced
117
Closed
58

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$19.5M
2
BCYC
Bicycle Therapeutics
BCYC
+$18.4M
3
INBX
Inhibrx, Inc. Common Stock
INBX
+$8.57M
4
IMTX icon
Immatics
IMTX
+$8.37M
5
AYLA
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
+$6.47M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$30.7M
2
ALEC icon
Alector
ALEC
+$14.1M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$11.5M
4
ANVS icon
Annovis Bio
ANVS
+$8.86M
5
CGEM icon
Cullinan Oncology
CGEM
+$7.61M

Sector Composition

Rank Sector Weight
1 Healthcare 30.01%
2 Consumer Staples 0.24%
3 Technology 0.17%
4 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
226
Cullinan Oncology
CGEM
$1.01B
– –
-295,596
Closed -$7.61M
CVM icon
227
CALL
CEL-SCI Corp
CVM
$20.3M
– –
-10,000
Closed -$2.6M
CYTK icon
228
Cytokinetics
CYTK
$10.5B
– –
-120,895
Closed -$2.39M
EYPT icon
229
CALL
EyePoint Inc
EYPT
$1.03B
– –
-208,500
Closed -$1.88M
FATE icon
230
Fate Therapeutics
FATE
$286M
– –
-3,600
Closed -$282K
KYNB
231
CALL
Kyntra Bio
KYNB
$27.2M
– –
-10,000
Closed -$6.66M
KYNB
232
PUT
Kyntra Bio
KYNB
$27.2M
– –
-7,752
Closed -$5.16M
FULC icon
233
Fulcrum Therapeutics
FULC
$273M
– –
-162,700
Closed -$1.71M
GILD icon
234
CALL
Gilead Sciences
GILD
$162B
– –
-80,000
Closed -$5.51M
LKFT
235
CALL
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
– –
-100,000
Closed -$6.89M
ICAD
236
DELISTED
iCAD Inc
ICAD
– –
-128,137
Closed -$2.22M
NBP
237
NovaBridge Biosciences American Depositary Shares
NBP
$185M
– –
-46,066
Closed -$3.87M
IMVT icon
238
CALL
Immunovant
IMVT
$7.93B
– –
-400,000
Closed -$4.23M
IMVT icon
239
PUT
Immunovant
IMVT
$7.93B
– –
-57,700
Closed -$610K
JETS icon
240
CALL
US Global Jets ETF
JETS
$776M
– –
-200,000
Closed -$4.84M
KRRO icon
241
Korro Bio
KRRO
$150M
– –
-1,398
Closed -$696K
KRRO icon
242
PUT
Korro Bio
KRRO
$150M
– –
-2,016
Closed -$1M
LLY icon
243
Eli Lilly
LLY
$1.02T
– –
-5,677
Closed -$1.3M
MCRB icon
244
CALL
Seres Therapeutics
MCRB
$46.8M
– –
-25,000
Closed -$11.9M
NTLA icon
245
CALL
Intellia Therapeutics
NTLA
$1.49B
– –
-294,400
Closed -$47.7M
RAPT
246
PUT
DELISTED
RAPT Therapeutics
RAPT
– –
-43,750
Closed -$11.1M
RCUS icon
247
PUT
Arcus Biosciences
RCUS
$3.55B
– –
-245,500
Closed -$6.74M
RDNT icon
248
RadNet
RDNT
$5.02B
– –
-110,647
Closed -$3.73M
RLMD icon
249
CALL
Relmada Therapeutics
RLMD
$557M
– –
-203,400
Closed -$6.51M
SAGE
250
CALL
DELISTED
Sage Therapeutics
SAGE
– –
-254,300
Closed -$14.4M
7 8 9
10
11

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Ikarian Capital held 267 positions worth $1.42B, up 15% from $1.24B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Ikarian Capital deployed $291M of net new capital in Q3 2021, opening 57 new positions and adding to 30 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 44% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Biogen, an estimated $30.7M trimmed.

  • Ikarian Capital's largest Q3 2021 buy was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.
  • Ikarian Capital added most to Inhibrx, Inc. Common Stock in Q3 2021, an estimated $8.57M increase.
  • Ikarian Capital's biggest Q3 2021 reduction was Biogen, cutting an estimated $30.7M.
  • Ikarian Capital fully exited Alector in Q3 2021, selling an estimated $14.1M.
  • Ikarian Capital's ten largest holdings make up 38% of its $1.42B portfolio in Q3 2021.
  • Ikarian Capital opened 57 new positions and closed 58 in Q3 2021.
  • Ikarian Capital's portfolio value rose 15% quarter-over-quarter to $1.42B.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.